Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. (Q53168966)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. (English)

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22454415

Rodney J. Hicks

12

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22454415

10

object named as

Keith T Flaherty

1 reference

Europe PubMed Central

29 June 2018

4

object named as

Antoni Ribas

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

9

object named as

Keith Nolop

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

Jeffrey A Sosman

7

object named as

Jeffrey A Sosman

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

author name string

Igor Puzanov

2

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

Ravi Amaravadi

3

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

Paul Chapman

5

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

Kevin B Kim

6

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

Richard J Lee

8

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

Jason Callahan

11

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

language of work or name

0 references

publication date

26 March 2012

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

Journal of Clinical Oncology

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

30

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

14

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

1628-1634

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

KIT as a therapeutic target in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Understanding the Warburg effect: the metabolic requirements of cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Somatic activation of KIT in distinct subtypes of melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Distinct sets of genetic alterations in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Mutations of the BRAF gene in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

30 June 2018

Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

13 August 2018

A novel cross-talk between endothelin-1 and cyclic AMP signaling pathways in the regulation of GLUT1 transcription in 3T3-L1 adipocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

13 August 2018

High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

13 August 2018

Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

13 August 2018

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

13 August 2018

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950495

13 August 2018

Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc

1 reference

https://pubmed.ncbi.nlm.nih.gov/22454415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.39.1938

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

1 reference

Europe PubMed Central

29 June 2018

http://europepmc.org/abstract/PMC/5950495

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53168966&oldid=2119052195"